Electrocore LLC (ECOR) Peer Comparison

$9.30

$-0.42 (-4.27%)

As on 28-Aug-2026 13:30EDT

Market cap

$95 Mln

Revenue (TTM)

$37 Mln

P/E Ratio

--

P/B Ratio

34.9

Div. Yield

0 %

Edit

	Electrocore LLC (ECOR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	95	12,753	10,906	10,222	9,762
Revenue ($ Mln)	37	1,505	613	785	2,589
Net Profit ($ Mln)	-14.77	160.59	-188.05	41.54	222.40
Net Margin (%)	-39.96	10.67	-30.68	5.29	8.59
RoE (%)	--	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.57	44.47
Price-To-Book	34.89	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Electrocore LLC (ECOR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	36.97	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	4.79	483.98	127.96	384.30	1,245.50
Gross Profit	27.79	942.44	393.22	347.62	1,343.60
Operating Expenses	46.09	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-13.91	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-15.04	203.83	-192.83	52.15	350.40
Provision for Tax	-0.27	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-14.77	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Electrocore LLC (ECOR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	-2.79	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	8.18	210.18	135.71	705.49	2,116.80
Current Liabilities	11.67	233.78	102.33	132.66	961.30
Total Liabilities	18.67	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Electrocore LLC (ECOR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	2.94	630.60	404.74	1,749.63	7,231.50
Current Assets	14.12	1,344.12	515.78	1,200.55	3,020.50
Total Assets	18.67	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	9.56	212.71	102.84	690.94	1,203.70
Net Current Assets	2.45	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Electrocore LLC (ECOR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-8.19	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	3.88	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	7.63	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Electrocore LLC (ECOR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-144.17	11.76	-22.53	1.79	8.98
ROE (%)	-478.70	10.86	-28.10	1.97	3.04
ROA (%)	-55.83	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-30.11	13.63	-30.58	9.87	-5.99
Net Margin (%)	-39.96	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Electrocore LLC (ECOR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	33.45	17.55	41.55	16.49	1.37
EBIT Growth (%)	16.09	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	-11.46	8.72	-102.66	400.42	-30.32
EPS Growth (%)	-3.03	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-321.67	17.33	-12.65	2.16	2.19

Valuation Ratios

	Electrocore LLC (ECOR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-2.57	68.93	-34.59	189.42	--
Price / Book Value	-21.01	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-2.88	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Electrocore LLC (ECOR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	-2.07	0.00	0.00	0.26	0.11
Short term debt to equity ratio	-0.50	0.01	0.00	0.01	0.06
Current Ratio	1.21	5.75	5.04	9.05	3.14
Quick Ratio	1.00	3.86	4.46	7.64	2.33
Interest Coverage	-11.84	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Electrocore LLC (ECOR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	2.46	12.65	22.67	20.09	17.06
Asset Turnover	1.40	0.74	0.59	0.26	0.24
Receivable days	13.65	46.54	60.95	72.41	65.39
Inventory Days	142.30	331.92	193.84	146.53	221.09
Payable days	195.32	26.16	60.19	29.05	37.02
Cash Conversion Cycle	-39.37	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly